Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL

Hypothesis- lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.
Chronic Lymphocytic Leukemia(CLL)|Small Lymphocytic Lymphoma
DRUG: Revlimid|DRUG: Azacitidine
the Rate of Response to the Combination of Azacitidine + Lenalidomide in Select Patients, the rate of response to the combination of azacitidine + lenalidomide in select patients with relapsed/refractory CLL and small lymphocytic lymphoma (SLL)., 9 Months
Assess for Treatment Related Toxicity Following Administration of Lenalidomide/ Azacitidine., 30 days after treatment completion (up to 10 Months)|The Progression Free Survival of Patients Treated With the Combination of Lenalidomide and Azacitidine, 9 Months|The Overall Survival of Patients Treated With the Combination of Lenalidomide and Azacitidine, 9 Months
Treatment response of lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.